Who's winning the war? Molecular mechanisms of antibiotic resistance in Helicobacter pylori

Kathleen R. Jones, Jeong Heon Cha, D. Scott Merrell

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

The ability of clinicians to wage an effective war against many bacterial infections is increasingly being hampered by skyrocketing rates of antibiotic resistance. Indeed, antibiotic resistance is a significant problem for treatment of diseases caused by virtually all known infectious bacteria. The gastric pathogen Helicobacter pylori is no exception to this rule. With more than 50% of the world's population infected, H. pylori exacts a tremendous medical burden and represents an interesting paradigm for cancer development; it is the only bacterium that is currently recognized as a carcinogen. It is now firmly established that H. pylori infection is associated with diseases such as gastritis, peptic and duodenal ulceration and two forms of gastric cancer, gastric adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma. With such a large percentage of the population infected, increasing rates of antibiotic resistance are particularly vexing for a treatment regime that is already fairly complicated; treatment consists of two antibiotics and a proton pump inhibitor. To date, resistance has been found to all primary and secondary lines of antibiotic treatment as well as to drugs used for rescue therapy.

Original languageEnglish
Pages (from-to)190-203
Number of pages14
JournalCurrent Drug Therapy
Volume3
Issue number3
DOIs
Publication statusPublished - 2008 Sep 1

Fingerprint

Microbial Drug Resistance
Helicobacter pylori
Stomach Neoplasms
Drug Repositioning
Anti-Bacterial Agents
Bacteria
Marginal Zone B-Cell Lymphoma
Proton Pump Inhibitors
Salaries and Fringe Benefits
Helicobacter Infections
Gastritis
Gastric Mucosa
Bacterial Infections
Carcinogens
Population
Digestion
Stomach
Adenocarcinoma
Warfare
Neoplasms

All Science Journal Classification (ASJC) codes

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

@article{6abdd240a9814022a72b658e08d330c4,
title = "Who's winning the war? Molecular mechanisms of antibiotic resistance in Helicobacter pylori",
abstract = "The ability of clinicians to wage an effective war against many bacterial infections is increasingly being hampered by skyrocketing rates of antibiotic resistance. Indeed, antibiotic resistance is a significant problem for treatment of diseases caused by virtually all known infectious bacteria. The gastric pathogen Helicobacter pylori is no exception to this rule. With more than 50{\%} of the world's population infected, H. pylori exacts a tremendous medical burden and represents an interesting paradigm for cancer development; it is the only bacterium that is currently recognized as a carcinogen. It is now firmly established that H. pylori infection is associated with diseases such as gastritis, peptic and duodenal ulceration and two forms of gastric cancer, gastric adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma. With such a large percentage of the population infected, increasing rates of antibiotic resistance are particularly vexing for a treatment regime that is already fairly complicated; treatment consists of two antibiotics and a proton pump inhibitor. To date, resistance has been found to all primary and secondary lines of antibiotic treatment as well as to drugs used for rescue therapy.",
author = "Jones, {Kathleen R.} and Cha, {Jeong Heon} and Merrell, {D. Scott}",
year = "2008",
month = "9",
day = "1",
doi = "10.2174/157488508785747899",
language = "English",
volume = "3",
pages = "190--203",
journal = "Current Drug Therapy",
issn = "1574-8855",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

Who's winning the war? Molecular mechanisms of antibiotic resistance in Helicobacter pylori. / Jones, Kathleen R.; Cha, Jeong Heon; Merrell, D. Scott.

In: Current Drug Therapy, Vol. 3, No. 3, 01.09.2008, p. 190-203.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Who's winning the war? Molecular mechanisms of antibiotic resistance in Helicobacter pylori

AU - Jones, Kathleen R.

AU - Cha, Jeong Heon

AU - Merrell, D. Scott

PY - 2008/9/1

Y1 - 2008/9/1

N2 - The ability of clinicians to wage an effective war against many bacterial infections is increasingly being hampered by skyrocketing rates of antibiotic resistance. Indeed, antibiotic resistance is a significant problem for treatment of diseases caused by virtually all known infectious bacteria. The gastric pathogen Helicobacter pylori is no exception to this rule. With more than 50% of the world's population infected, H. pylori exacts a tremendous medical burden and represents an interesting paradigm for cancer development; it is the only bacterium that is currently recognized as a carcinogen. It is now firmly established that H. pylori infection is associated with diseases such as gastritis, peptic and duodenal ulceration and two forms of gastric cancer, gastric adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma. With such a large percentage of the population infected, increasing rates of antibiotic resistance are particularly vexing for a treatment regime that is already fairly complicated; treatment consists of two antibiotics and a proton pump inhibitor. To date, resistance has been found to all primary and secondary lines of antibiotic treatment as well as to drugs used for rescue therapy.

AB - The ability of clinicians to wage an effective war against many bacterial infections is increasingly being hampered by skyrocketing rates of antibiotic resistance. Indeed, antibiotic resistance is a significant problem for treatment of diseases caused by virtually all known infectious bacteria. The gastric pathogen Helicobacter pylori is no exception to this rule. With more than 50% of the world's population infected, H. pylori exacts a tremendous medical burden and represents an interesting paradigm for cancer development; it is the only bacterium that is currently recognized as a carcinogen. It is now firmly established that H. pylori infection is associated with diseases such as gastritis, peptic and duodenal ulceration and two forms of gastric cancer, gastric adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma. With such a large percentage of the population infected, increasing rates of antibiotic resistance are particularly vexing for a treatment regime that is already fairly complicated; treatment consists of two antibiotics and a proton pump inhibitor. To date, resistance has been found to all primary and secondary lines of antibiotic treatment as well as to drugs used for rescue therapy.

UR - http://www.scopus.com/inward/record.url?scp=54849407182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54849407182&partnerID=8YFLogxK

U2 - 10.2174/157488508785747899

DO - 10.2174/157488508785747899

M3 - Review article

AN - SCOPUS:54849407182

VL - 3

SP - 190

EP - 203

JO - Current Drug Therapy

JF - Current Drug Therapy

SN - 1574-8855

IS - 3

ER -